Final results of a phase I study of cabozantinib (cabo) plus nivolumab (nivo) and cabonivo plus ipilimumab (Ipi) in patients (pts) with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies

被引：0
|
作者：
Nadal, R. [1 ]
Mortazavi, A. [2 ]
Stein, M. [3 ]
Pal, S. K. [4 ]
Davarpanah, N. [1 ]
Parnes, H. L. [1 ]
Ning, Y. M. [1 ]
Cordes, L. M. [1 ]
Lin, J. [1 ]
Bagheri, M. [5 ]
Linderberg, L. [1 ]
Berniger, M. [1 ]
Steinberg, S. M. [6 ]
Moore, T. [4 ]
Lancaster, T. [2 ]
Aviles, M. [3 ]
Costello, R. [1 ]
Bottaro, D. P. [1 ]
Dahut, W. L. [1 ]
Apolo, A. B. [1 ]
机构：
[1] NCI, Med Oncol, Ctr Canc Res, Bethesda, MD 20892 USA
[2] Ohio State Univ, Internal Med, James Canc Hosp, Columbus, OH 43210 USA
[3] Canc Inst New Jersey, Div Med Oncol, New Brunswick, NJ USA
[4] City Hope Natl Med Ctr, Med Oncol, Duarte, CA USA
[5] NCI, Ctr Canc Res, Radiol & Imaging Sci, Bethesda, MD 20892 USA
[6] NCI, Ctr Canc Res, Biostat & Data Management Sect, Bethesda, MD 20892 USA
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
846O
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Clinical efficacy of cabozantinib plus nivolumab (CaboNivo) and CaboNivo plus ipilimumab (CaboNivoIpi) in patients (pts) with chemotherapy-refractory metastatic urothelial carcinoma (mUC) either naive (n) or refractory (r) to checkpoint inhibitor (CPI)
    Nadal, Rosa
    Mortazavi, Amir
    Stein, Mark N.
    Pal, Sumanta K.
    Lee, Daniel K.
    Parnes, Howard L.
    Ning, Yang-Min
    Cordes, Lisa M.
    Bagheri, Mohammadhadi H.
    Thompson, Ryan
    Mayfield, Christian
    Steinberg, Seth M.
    Monk, Paul
    Lara, Primo
    Costello, Rene
    Agarwal, Piyush K.
    Bottaro, Donald
    Dahut, William L.
    Apolo, Andrea B.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [12] Phase I expansion study of cabozantinib plus nivolumab (CaboNivo) in metastatic urothelial carcinoma (mUC) patients (pts) with progressive disease following immune checkpoint inhibitor (ICI) therapy.
    Girardi, Daniel da Motta
    Niglio, Scot Anthony
    Mortazavi, Amir
    Lara, Primo
    Pal, Sumanta K.
    Saraiya, Biren
    Cordes, Lisa M.
    Ley, Lisa
    Ortiz, Olena Sierra
    Cadena, Jacqueline
    Diaz, Carlos
    Bagheri, Mohammadhadi H.
    Steinberg, Seth M.
    Costello, Rene
    Streicher, Howard
    Wright, John
    Parnes, Howard L.
    Ning, Yang-Min
    Bottaro, Donald P.
    Apolo, Andrea B.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [13] Evaluation of the clinical activity of ipilimumab (IPI) plus nivolumab (NIVO) in patients (pts) with NIVO-refractory metastatic urothelial cancer (UC).
    Callahan, Margaret K.
    Kania, Brooke Elizabeth
    Iyer, Gopa
    Clement, Jessica Mary
    Funt, Samuel
    McCoy, Asia S.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [14] Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors
    Apolo, Andrea B.
    Nadal, Rosa
    Girardi, Daniel M.
    Niglio, Scot A.
    Ley, Lisa
    Cordes, Lisa M.
    Steinberg, Seth M.
    Sierra Ortiz, Olena
    Cadena, Jacqueline
    Diaz, Carlos
    Mallek, Marissa
    Davarpanah, Nicole N.
    Costello, Rene
    Trepel, Jane B.
    Lee, Min-Jung
    Merino, Maria J.
    Bagheri, Mohammad Hadi
    Monk, Paul
    Figg, William D.
    Gulley, James L.
    Agarwal, Piyush K.
    Valera, Vladimir
    Chalfin, Heather J.
    Jones, Jennifer
    Streicher, Howard
    Wright, John J.
    Ning, Yangmin M.
    Parnes, Howard L.
    Dahut, William L.
    Bottaro, Donald P.
    Lara, Primo N., Jr.
    Saraiya, Biren
    Pal, Sumanta K.
    Stein, Mark N.
    Mortazavi, Amir
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (31) : 3672 - +
  • [15] Phase I/II study of ipilimumab plus nivolumab (IPI-NIVO) combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma
    Jain, R. K.
    Chahoud, J.
    Chatwal, M.
    Kim, Y.
    Dhillon, J.
    Vosoughi, A.
    Araujo, C.
    Li, R.
    Zhang, J.
    Sonpavde, G. P.
    ANNALS OF ONCOLOGY, 2021, 32 : S724 - S724
  • [16] Phase I/IB trial of sitravatinib (Sitra) plus nivolumab (Nivo) plus ipilimumab (Ipi) in patients (pts) with advanced clear cell renal cell carcinoma (accRCC) or other solid malignancies.
    Msaouel, Pavlos
    Gao, Jianjun
    Yuan, Ying
    Siefker-Radtke, Arlene O.
    Jonasch, Eric
    Goswami, Sangeeta
    Zurita, Amado J.
    Campbell, Matthew T.
    Shah, Amishi Yogesh
    Corn, Paul G.
    Ramos, Claudia
    Yan, Xiaohong
    Chin, Curtis
    Der-Torossian, Hirak
    Tannir, Nizar M.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [17] Phase Ib trial of selinexor (SEL) in combination with nivolumab (NIVO) alone or nivolumab plus ipilimumab (NIVO plus IPI) in patients (pts) with advanced malignancies: The renal cell carcinoma (RCC) experience.
    Alhalabi, Omar
    Tannir, Nizar M.
    Momin, Hassan Ahmed
    Yilmaz, Bulent
    Stephen, Bettzy
    Ejezie, Chinenye Lynette
    Moyers, Justin Tyler
    Gurses, Serdar A.
    How, Jeffrey
    Fu, Siqing
    Ahnert, Jordi Rodon
    Hong, David S.
    Piha-Paul, Sarina Anne
    Subbiah, Vivek
    Dumbrava, Ecaterina Elena
    Karp, Daniel D.
    Janku, Filip
    Meric-Bernstam, Funda
    Naing, Aung
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [18] Phase I/II study of ipilimumab plus nivolumab (IPI-NIVO) combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma.
    Jain, Rohit K.
    Yang, Yuanquan
    Chadha, Juskaran
    Zhang, Jingsong
    Raymond, Sarah
    Oschmann, Erika
    Poehlman, Trey
    Fan, Wenyi
    Kim, Youngchul
    Dhillon, Jasreman
    Chahoud, Jad
    Chatwal, Monica Sheila
    Sonpavde, Guru P.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS713 - TPS713
  • [19] Final results from a phase I trial and expansion cohorts of cabozantinib and nivolumab (CaboNivo) alone or with ipilimumab (CaboNivoIpi) for metastatic genitourinary tumors.
    Apolo, Andrea B.
    Girardi, da Motta Daniel
    Niglio, Scot Anthony
    Nadal, Rosa Maria
    Cordes, Lisa M.
    Steinberg, Seth M.
    Costello, Rene
    Trepel, Jane B.
    Lee, Sunmin
    Lee, Min-Jung
    Cao Liang
    Gulley, James L.
    Bottaro, Donald P.
    Saraiya, Biren
    Pal, Sumanta K.
    Quinn, David, I
    Lara, Primo Lucky N.
    Parnes, Howard L.
    Dahut, William L.
    Mortazavi, Amir
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [20] Final results from phase I trial of cabozantinib/nivolumab (CaboNivo) alone or with ipilimumab (CaboNivoIpi) and peripheral immunity in metastatic genitourinary (mGU) tumors
    Kydd, A. R.
    Lee, M-J.
    Lee, S.
    Rastogi, S.
    Sato, N.
    Cordes, L.
    Ley, L.
    Ortiz, O. Sierra
    Wright, J. J.
    Streicher, H.
    Steinberg, S.
    Saraiya, B.
    Pal, S. K.
    Lara, P. N.
    Mortazavi, A.
    Costello, R.
    Niglio, S.
    Bottaro, D.
    Trepel, J.
    Apolo, A. B.
    ANNALS OF ONCOLOGY, 2021, 32 : S690 - S690
12345